Sat, Mar 25, 2017 | updated 11:21 AM IST

Indigenous technology to bring down costs of life-saving medicines

Updated: Oct 17, 2016 12:49 IST

Chandigarh [India], Oct. 17 (ANI): Scientists at CSIR-Institute of Microbial Technology (IMTECH) have developed a technology to produce biotherapeutic proteins like Erythropoietin and Streptokinase.

The indigenous technology will bring down costs of insulin, medicines for Hepatitis B, Cancer, anaemia, heart attack and several other diseases drastically.

Currently, India imports patented Biotherapeutic proteins for production of insulin, Streptokinase (blood clot buster), Hepatitis B vaccine, etc, despite India's pre-eminence as the largest exporter of generic medicines worldwide.

Erythropoietin is a key component for anti-anaemic medicines, while Streptokinase is for treatment of blood clots that blocked arteries or lung blood clots (pulmonary embolism) as well as leg blood clots (deep venous thrombosis-DVT).

"These technologies involve expressing the genes for the therapeutic proteins in different microbial hosts like bacteria and yeasts. The latter include the well known baker's yeast and Pichia pastoris. The cost advantage and ease of production of proteins have made the recombinant yeast based technologies prevalent worldwide which hold a major share of world therapeutic protein market," said Jagmohan Singh, the Chief Scientist.

Singh has developed an indigenous technology platform for commercial scale production of Biotherapeutic Proteins to make these basic life-saving drugs accessible to the masses at cheaper costs.

The new system, which is based on Schizosaccharomyces pombe commonly known as fission yeast, has great potential to produce vaccines like Hepatitis B surface antigen vaccine (HBS) and other therapeutic proteins at a lower cost than that produced in Pichia. This technology can be extended to produce other proteins, like Erythropoietin, antibodies, etc.

The current cost of hepatitis B vaccine in India ranges from Rs. 45 (Serum Institute) to Rs. 250 per paediatric dose of 10 microgram in 0.5 ml. In USA it is about $25 per dose. The cost of adult dose of 20 microgram is nearly double. The normal regimen of vaccination involves 3 such injections. The indigenous technology would bring down the cost to less than Rs. 10, when commercially produced.

India has over 40 million Hepatitis B infected patients, second only to China.

Most Hepatitis B patients are unaware of their infection, putting them at serious risk of developing cirrhosis or liver cancer, which is life-threatening.

Similarly, the price of insulin varies from Rs. 140 to Rs. 325/- per injection in India, while in USA it is about $13 per injection. The slow release variant of insulin called Glargine costs from Rs. 410 to 1475 in India and $250-$275 for a 10 ml vial in USA and Canada.

This would be brought down to a third, once the technology developed by IMTECH is commercialised.

"So far we have expressed hepatitis B vaccine at bench scale in fission yeast. Once the production is scaled up, the production cost could be around Re. 1 per dose, while the lowest cost reported for Pichia-based system Rs. 45/- dose," Singh said.

Adding, "Even this is beyond the reach of people below poverty line. Thus, there is scope to bring the commercial price of Hepatitis B vaccine further down. Once the proof-of- concept stage is complete, we will undertake expression of other proteins like insulin, antibodies, etc in fission yeast."

The worldwide market of recombinant Hepatitis B (HBS) vaccine is more than US$ 3.2 billion. The market for anticancer monoclonal antibodies is even bigger and growing.

However, most of the technologies or products are imported. Furthermore, currently popular system of Pichia is patented. This implies payment of large fees by the Indian Biotech companies to the inventor, which adds to the cost of the vaccine.

Pichia vector is generally licensed for commercial research for USD 50,000 with an annual maintenance fee of $ 5,000-30,000. In case the product is commercialized the fee is $75,000 plus royalty ranging from 3-5%," he said.

"While providing protein drugs at lower cost, it would also be a money generator if the technology is commercially exploited worldwide. This is a timely invention as Indian Biotech Industry is poised to enter the multibillion dollar market of biosimilar therapeutic proteins," he concluded. (ANI)

Washington D.C. [USA], Mar. 25 (ANI): Scientists have found that stem cell therapy repairs damaged lungs - raising hopes of a cure for the crippling chronic obstructive pulmonary disease (COPD) and cystic fibrosis.

Full Story >>

New method can cut dental implant failure

Updated: Mar 25, 2017 09:34 IST

Washington D.C. [USA], Mar. 25 (ANI): A team of researchers has come up with a new method to reduce dental implant failure.

Full Story >>

Washington D.C. [USA], Mar. 25 (ANI): A team of researchers has come up with a fluorogenic probe that can detect the activity of multidrug-resistant pathogens in an assay system.

Full Story >>

Virus hydrophobicity can help purify vaccines

Updated: Mar 25, 2017 07:46 IST

Washington D.C. [USA], Mar. 25 (ANI): A team of researchers has found that hydrophobic proteins on virus surfaces can help purify vaccines.

Full Story >>

Washington D.C. [USA], Mar. 25 (ANI): A team of researchers has shed light on why survivors of childhood brain tumours may be prone to heart disease, stroke, type 2 diabetes and early death.

Full Story >>

New Delhi [India], Mar. 24 (ANI): Continuing its efforts to raise awareness on tuberculosis and its diagnosis, Division of Clinical Microbiology & Molecular Medicine Department of Laboratory Medicine, AIIMS, and BD (Becton Dickinson India) for the third consecutive year organized a symposium today on "challenges in diagnosis and eradication of tuberculosis".

Full Story >>

New Delhi [India], Mar. 24 (ANI): On the solemn occasion of World Tuberculosis (TB) Day, Members of Parliament, policymakers, TB patients, survivors, and citizens of the civil society gathered at India Gate on Thursday, March 23 to pay tribute to the nearly five lakh lives lost due to this disease last year.

Full Story >>

New Delhi [India], Mar. 24 (ANI): Emergence of multi drug resistant TB and complications aggravated by high rates of co-infection with HIV-AIDS has renewed the threat of TB epidemic in India. With widespread prevalence of the infection, children experience a serious risk of contracting Tuberculosis, especially if they are under-nourished.

Full Story >>

New Delhi [India], Mar. 24 (ANI): Tuberculosis can affect any age, caste or class and it is one of the top 10 causes of death across the globe, ranking above HIV and malaria.

Full Story >>

New Delhi [India], Mar. 24 (ANI): Tuberculosis is one of the top 10 causes of death across the globe, ranking above HIV and malaria. According to the World Health Organization (WHO), in 2015, there were 10.4 million new cases of TB worldwide.

Full Story >>

London [UK], Mar. 23 (ANI): Want happy families? Then delay your decision to start a family, as a study suggests, children born to older mother experience have fewer behavioural, social and emotional problems.

Full Story >>

Washington D.C. [USA], Mar. 23 (ANI): For women, stay fit and maintain a healthy weight, as a study finds a higher waist-to-hip ratios increases the risk of ovarian cancer risk by more than a fifth.

Full Story >>

Washington D.C. [USA], Mar. 23 (ANI): A study finds that people who are born blind have heightened sense of hearing, smell and touch, suggesting that their brain "rewires" itself in the absence of visual information to boost other senses.

Full Story >>

New Delhi [India], Mar. 23 (ANI): For those suffering with age-related (degenerative) arthritis of the knee, a stage comes when all the reasonable non-operative options stops working.

Full Story >>

Hepatitis drug can help cut Ebola death rate

Updated: Mar 22, 2017 09:30 IST

Washington D.C. [USA], Mar. 22 (ANI): A class of drugs used to treat hepatitis and some forms of multiple sclerosis has shown promise in treating Ebola.

Full Story >>

Weekend surgery 'not riskier'

Updated: Mar 22, 2017 09:20 IST

Washington D.C. [USA], Mar. 22 (ANI): Day of the week has no impact on the survival chances of people undergoing emergency surgery, a new research has found.

Full Story >>

Washington D.C. [USA], Mar. 22 (ANI): Despite existing prevention methods, transmission of infections with HIV, hepatitis B, syphilis or rubella from mother to child before and during birth as well as in infancy still occur across Europe.

Full Story >>

Changes in blood may spur Alzheimer's disease

Updated: Mar 22, 2017 07:29 IST

Washington D.C. [USA], Mar. 22 (ANI): A recent study has linked changes in the vascular system to Alzheimer's disease.

Full Story >>

Spraying onto broken hearts to heal them

Updated: Mar 22, 2017 06:45 IST

Washington D.C. [USA], Mar. 22 (ANI): A team of scientist has come up with a new method that may make the heart surgeries a history.

Full Story >>

Washington D.C. [USA], Mar. 22 (ANI): With both tourism and casual "hookup" sex on the rise among college-age adults, there's an urgent need for gender-sensitive and age-appropriate sexual health campaigns that are tailored to young women's motivations for taking sexual risks while travelling, a new study has suggested.

Full Story >>